| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 15/06/2023 | 12:33 | Edgar (US Regulatory) | Securities Registration Statement (s-1) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 12/06/2023 | 12:43 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 12/06/2023 | 12:43 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 19/05/2023 | 23:28 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 03/05/2023 | 22:43 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 28/04/2023 | 20:10 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 28/04/2023 | 17:20 | Edgar (US Regulatory) | Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 27/04/2023 | 12:07 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 12/04/2023 | 12:02 | Edgar (US Regulatory) | Securities Registration Statement (s-1/a) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 14/02/2023 | 23:28 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 27/01/2023 | 22:11 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 17/01/2023 | 18:52 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 29/12/2022 | 15:37 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 20/12/2022 | 22:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 13/12/2022 | 15:07 | Edgar (US Regulatory) | Sec Staff Action/letter (sec Staff) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 13/12/2022 | 12:01 | Edgar (US Regulatory) | Certification by the Exchange Approving Securities for Listing (cert) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 13/12/2022 | 03:05 | PR Newswire (US) | ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA") | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 22/11/2022 | 13:05 | PR Newswire (US) | ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 15/11/2022 | 17:52 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 15/11/2022 | 13:05 | PR Newswire (US) | SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 14/11/2022 | 23:36 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 03/11/2022 | 22:34 | Edgar (US Regulatory) | Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 28/10/2022 | 13:05 | PR Newswire (US) | ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 27/09/2022 | 19:00 | PR Newswire (US) | ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 22/08/2022 | 14:05 | PR Newswire (US) | Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 15/08/2022 | 14:05 | PR Newswire (US) | Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 12/08/2022 | 22:37 | Edgar (US Regulatory) | Securities Registration: Business Combination (s-4) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 03/08/2022 | 13:05 | PR Newswire (US) | ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 20/07/2022 | 23:30 | PR Newswire (US) | ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp. | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |
| 31/03/2022 | 17:05 | Edgar (US Regulatory) | Notification That Annual Report Will Be Submitted Late (nt 10-k) | NASDAQ:LSPR | Larkspur Health Acquisition Corporation |